02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
13:51 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute promyelocytic leukemia (APL); breast cancer Cell culture and mouse studies suggest liposomal co-delivery of the antioxidant quercetin and doxorubicin could help treat doxorubicin-resistant APL, breast cancer and other cancers. In doxorubicin-resistant human APL...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Company News

Huya, School of Chinese Materia Medica at the Beijing University of Chinese Medicine deal

Huya will have the rights of first review and access to drug candidates owned or controlled by the university. Huya said the partnership will strengthen its R&D related to traditional Chinese medicine. The university will...